Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neha Korde

Showing results (71-80 of 125) with videos related to

Pageof 13
Sort By:
Hemasphere|April 20, 2026
Whole-genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myelomaChrissy Baker, Elizabeth Hill, Dickran Kazandjian, et al.
Haematologica|March 25, 2014
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myelomaNeha Korde, Mattias Carlsten, Min-Jung Lee, et al.
Blood Cancer Journal|October 13, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myelomaTara Sebastian, Sridevi Rajeeve, Tasmin Farzana, et al.
JAMA Oncology|July 19, 2019
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple MyelomaOla Landgren, Jonathan N Hofmann, Charlene M McShane, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Blood Cancer Journal|May 1, 2026
A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patientsRoss S Firestone, Anish K Simhal, Theresia Akhlaghi, et al.
Blood Advances|September 29, 2023
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groupsUrvi A Shah, Erin Moshier, Andriy Derkach, et al.
Leukemia & Lymphoma|December 23, 2015
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imagingManisha Bhutani, Baris Turkbey, Esther Tan, et al.
Leukemia & Lymphoma|October 25, 2022
A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapyKarthik Nath, Tala Shekarkhand, Meghan Salcedo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaSusan Bal, Heather J Landau, Gunjan L Shah, et al.
Pageof 13

Showing results (71-80 of 125) with videos related to

Sort By:
Pageof 13
Hemasphere|April 20, 2026
Whole-genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myelomaChrissy Baker, Elizabeth Hill, Dickran Kazandjian, et al.
Haematologica|March 25, 2014
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myelomaNeha Korde, Mattias Carlsten, Min-Jung Lee, et al.
Blood Cancer Journal|October 13, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myelomaTara Sebastian, Sridevi Rajeeve, Tasmin Farzana, et al.
JAMA Oncology|July 19, 2019
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple MyelomaOla Landgren, Jonathan N Hofmann, Charlene M McShane, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Blood Cancer Journal|May 1, 2026
A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patientsRoss S Firestone, Anish K Simhal, Theresia Akhlaghi, et al.
Blood Advances|September 29, 2023
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groupsUrvi A Shah, Erin Moshier, Andriy Derkach, et al.
Leukemia & Lymphoma|December 23, 2015
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imagingManisha Bhutani, Baris Turkbey, Esther Tan, et al.
Leukemia & Lymphoma|October 25, 2022
A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapyKarthik Nath, Tala Shekarkhand, Meghan Salcedo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaSusan Bal, Heather J Landau, Gunjan L Shah, et al.
Pageof 13